Today, on April 18, 2016, Xvivo Perfusion AB published a press release with information about a public offer to the shareholders in Vivoline Medical AB. The current rules of First North state that a listed company will be given observation status if the company is subject to a public offer.
With reference to what is stated above, Nasdaq Stockholm AB has decided that the shares in Vivoline Medical (VIVO, ISIN code SE0006764387, order book ID 094166) will be given observation status.
For further information about this exchange notice please contact Cecilia Olsson or Karin Ydén, telephone + 46 8 405 60 00.
Nasdaq Stockholm AB
| Karin Ydén Head of Issuer Surveillance | Cecilia Olsson Senior Advisor, Issuer Surveillance |